**Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review**

Jorge E. Cortesa, Anna Candonib, Richard E. Clarkc, Brian Leberd, Pau Montesinose, Paresh Vyasf, Amer M. Zeidang and Michael Heuserh

aGeorgia Cancer Center, Augusta, GA, USA; bUniversity Hospital of Udine-ASUFC, Udine, Italy; cDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; dMcMaster University Medical Centre, Hamilton, ON, Canada; eHospital Universitari i Politècnic La Fe, Valencia, Spain, and CIBERONC, Instituto de Salud Carlos III, Madrid, Spain; fWeatherall Institute of Molecular Medicine, Oxford, UK; gYale School of Medicine, New Haven, CT, USA; hHannover Medical School, Hannover, Germany

**CONTACT:** Jorge E. Cortes; Georgia Cancer Center, 1410 Laney Walker Blvd, Augusta, GA 30912, USA; Phone: 706-721-0570; Email: jorge.cortes@augusta.edu

**Running head:** Glasdegib plus low-dose cytarabine for acute myeloid leukemia

**Target journal:** *Leukemia & Lymphoma*

**Word count:** 3545/4000 words  **Reference count:** 96 references **Table/figure count:** 6 tables and 2 figures (max 8 tables/figures)

**ABSTRACT (140/150 words)**

Glasdegib, in combination with low-dose cytarabine (LDAC), is the first Smoothened inhibitor approved for treatment of acute myeloid leukemia. Glasdegib plus LDAC is indicated for patients in whom therapy options are limited, e.g. older patients and those ineligible for intensive chemotherapy due to pre-existing comorbidities. This review summarizes the recommendations of a panel of hemato-oncologists regarding the selection of patients best suited for treatment with glasdegib plus LDAC and the management during therapy with this combination. The panel considered the impact of concomitant medications and comorbidities during treatment with glasdegib plus LDAC, and discussed common adverse events (AEs) associated with glasdegib plus LDAC. Management strategies for AEs discussed by the panel included dose modifications, supportive care therapies, and prophylactic treatments. Finally, the panel highlighted the importance of patient communication and education regarding the possible AEs that may occur during treatment.

**Keywords (3–6):** acute myeloid leukemia; adverse events; comorbidities;glasdegib; low-dose cytarabine; older patients

**Introduction**

Acute myeloid leukemia (AML) is a complex heterogeneous disease [[1-4](#_ENREF_1)]. Intensive induction/consolidation therapy gives the best chance for cure, but not all patients are candidates [[2](#_ENREF_2),[5-7](#_ENREF_5)]. Selection is mostly subjective assessment based on clinical observations, with no universally accepted or validated tools to determine eligibility. Characteristics commonly considered in clinical practice include age, Eastern Cooperative Oncology Group performance status (ECOG PS), cytogenetic risk, and comorbidities [[2](#_ENREF_2),[8-17](#_ENREF_8)]. In patients aged ≥60, the following variables were associated with complete remission (CR) or early death: age, de novo AML, laboratory parameters, and comorbidities [[18](#_ENREF_18)].

Evidence varies regarding intensive chemotherapy (IC) in older patients with AML [[13](#_ENREF_13),[19-29](#_ENREF_19)]. Improved outcomes and survival benefits were reported in patients aged ≥60 who received IC regimens versus those who received no treatment; in some reports, this was irrespective of comorbidity burden [[19-24](#_ENREF_19),[28](#_ENREF_28),[29](#_ENREF_29)]. Others indicated that, despite high rates of CR, only a carefully selected subset of older patients with AML can be considered for IC [[13](#_ENREF_13),[25-27](#_ENREF_25)].

Traditionally, patients ineligible for IC have been treated with low-dose cytarabine (LDAC) or hypomethylating agents (HMAs) [[2](#_ENREF_2),[5-7](#_ENREF_5)]. However, a clearer understanding of AML pathogenesis has led to new options, with treatment selection based on patient and disease characteristics. Although decisions are sometimes steered by objective criteria (e.g. FMS-like tyrosine kinase 3 [FLT3] inhibitor for patients with *FLT3* mutations), guidance is needed regarding patient selection and therapy management. A meeting of expert hemato-oncologists was held to define the use of glasdegib plus LDAC in treatment of older patients with AML, in particular, to define those best suited for this therapy and provide guidance on managing therapy-related adverse events (AEs). The recommendations of this expert panel are described here.

**Setting and methods**

On 12 April 2019 in London, UK, nine hemato-oncologists from centers across Europe, Canada, and the USA participated in an expert panel. All had extensive experience in treating AML and the use of glasdegib plus LDAC, glasdegib as monotherapy, and/or glasdegib in combination with other therapies in patients with AML.

The experts discussed their clinical experience with standard and experimental treatments for AML, patient characteristics that influence their decisions, and AE management with glasdegib plus LDAC. These discussions were captured and formed the foundation of this manuscript that underwent critical review by all experts.

**Approved treatments and related clinical trial experience**

A number of therapies are approved by the US Food and Drug Administration (FDA) and/or European Medicines Agency (EMA) for treatment of patients with AML ineligible for IC (Table 1 and Figure 1). Decision-making criteria regarding patient eligibility for IC are both subjective (e.g. inclusion/exclusion criteria, clinical trial characteristic) and objective (e.g. label indication, age, mutations) (Tables 2 and 3).

***Standard treatments***

Decitabine and azacitidine are standard-of-care therapies for older patients and those ineligible for IC; LDAC is another available alternative treatment [[30](#_ENREF_30)]. In a randomized study, LDAC 20 mg twice daily (BID) was compared with hydroxyurea in patients primarily aged ≥60 ineligible for chemotherapy. Patients aged <70 were required to have additional comorbidities that precluded chemotherapy [[31](#_ENREF_31)]. Median age was 74 (range: 51–90). CR was achieved in 18% (LDAC) and 1% (hydroxyurea) and overall survival (OS) was better with LDAC (*p*=.0009). Common all-causality AEs during course 1 were cardiac (10% and 11%), nausea (6% each), and diarrhea (4% and 10%) with LDAC and hydroxyurea, respectively [[31](#_ENREF_31)].

A phase 3 study evaluated decitabine (20 mg/m2 intravenous [IV] on a 5-day schedule) versus treatment choice in patients aged ≥65, ECOG PS 0–2, and poor/intermediate-risk cytogenetics [[32](#_ENREF_32)]. Median OS (mOS) and CR rates were 7.7 months and 15.7% (decitabine) and 5.0 months and 7.4% (treatment choice). Common all-causality AEs (grades 3–4) with decitabine and treatment choice, respectively, were thrombocytopenia (40% and 32%), anemia (34% and 25%), febrile neutropenia (32% and 22%), and neutropenia with decitabine (32%) [[32](#_ENREF_32)].

In a phase 3 study, patients aged ≥65 with poor/intermediate-risk cytogenetics received azacitidine (75 mg/m2/day) or conventional care regimens [[33](#_ENREF_33)]. mOS and CR were 10.4 months and 21.9% (azacitidine) and 6.5 months and 21.9% (conventional care). Common all-causality AEs for azacitidine, LDAC, and IC, respectively, were febrile neutropenia (28%, 30.1%, and 31%), neutropenia (26.3%, 24.8%, and 33.3%), and thrombocytopenia (23.7%, 27.5%, and 21.4%) [[33](#_ENREF_33)].

***Targeted therapies***

In recent years, a number of targeted therapies have become available, or are in clinical development, for patients ineligible for IC.

The Smoothened inhibitor (SMOi) glasdegib 100 mg once daily (QD) is FDA-approved in combination with LDAC 20 mg BID for patients with AML aged ≥75 or ineligible for induction IC [[34](#_ENREF_34)]. Glasdegib plus LDAC has been granted initial authorization by the EMA to treat newly diagnosed de novo or secondary AML in adult patients who are not candidates for standard induction chemotherapy AML [[35](#_ENREF_35)]. Approval of glasdegib was based on the results from the pivotal phase 2 BRIGHT MDS&AML 1003 trial [[36-39](#_ENREF_36)] (Table 4). In BRIGHT AML 1003, survival probability for glasdegib plus LDAC versus LDAC alone, respectively, was 39.4% and 8.4% at 1 year, and 19.0% and 2.8% at 2 years [[37](#_ENREF_37)]. In a quality-adjusted time without symptoms of disease progression or toxicities (Q-TWiST) analysis of BRIGHT AML 1003, patients receiving glasdegib plus LDAC had longer time in relatively ‘good’ health compared with those receiving LDAC alone [[40](#_ENREF_40)]. OS was similar, and CR rate was slightly lower, for LDAC alone in the BRIGHT MDS&AML 1003 study compared with the previous LDAC study, indicating that the LDAC control arm in BRIGHT MDS&AML 1003 is representative of the AML population [[31](#_ENREF_31)]. In BRIGHT MDS&AML 1012, 17% (MDS) and 20% (AML) achieved CR and mOS was not reached with glasdegib (100 mg QD) plus azacitidine (75 mg/m2/day) in either population [[41](#_ENREF_41),[42](#_ENREF_42)]. Glasdegib 100 mg QD is also being investigated in combination with decitabine 20 mg/m2 IV on a 5- or 10-day schedule in older patients with poor-risk AML (NCT04051996). Several other clinical trials of glasdegib as monotherapy or combination therapy in AML have completed or are underway, in particular, a phase 3 trial of glasdegib/placebo plus 7+3 or glasdegib/placebo plus azacitidine in untreated AML (NCT03416179/BRIGHT AML 1019), and a number of phase 2 trials in various patient populations with AML (NCT03390296, NCT03226418, NCT01841333), are ongoing.

The BCL-2 inhibitor venetoclax plus HMAs or LDAC is FDA-approved for treatment of newly diagnosed AML in patients aged ≥75 or ineligible for induction IC [[43](#_ENREF_43)]. A phase 1B study evaluated venetoclax (400, 800, or 1200 mg QD) plus HMAs in patients aged ≥65 ineligible for standard induction chemotherapy due to age ≥75, comorbidities (e.g. cardiac disease, prior anthracycline use, secondary AML [sAML]), or high probability of treatment-related mortality [[44](#_ENREF_44)]. mOS was 17.5 months, and 37% achieved CR. Common all-causality AEs (grades 3–4) were febrile neutropenia (43%), decreased white blood cell count (31%), and anemia (25%) [[44](#_ENREF_44)]. Neutropenia occurred among 40% of patients who experienced AEs leading to venetoclax dose interruption. Additionally, 33% of patients with neutropenia delayed cycle 2 treatment to allow absolute neutrophil count recovery [[44](#_ENREF_44)]. Another phase 1B/2 study assessed venetoclax 600 mg QD plus LDAC 20 mg/m2/day in patients aged ≥60 ineligible for IC due to comorbidity or other factors [[45](#_ENREF_45)]: ECOG PS 0–2 was required for patients aged ≥75; ECOG PS 0–3 for patients aged 60–74; an additional comorbidity for those with ECOG PS 0–1 [[45](#_ENREF_45)]. mOS was 10.1 months, and 26% achieved CR. Dose interruptions due to AEs occurred in 55% of patients and included delayed neutrophil (*n*=8) and platelet recovery (*n*=10). Dose reductions due to AEs (7%) were mostly due to thrombocytopenia. Common all-causality AEs were nausea (70%), diarrhea (49%), and hypokalemia (48%) [[45](#_ENREF_45)]. Interim results from a phase 3 study of venetoclax plus LDAC versus LDAC alone, respectively, reported mOS of 7.2 and 4.1 months and CR of 27.3% and 7.4%, a difference that was not statistically significant [[46](#_ENREF_46)].

Recurrent *IDH* mutations, found in ≈20% of AML cases, are associated with older age, intermediate-risk cytogenetics, and other mutations [[6](#_ENREF_6),[47](#_ENREF_47),[48](#_ENREF_48)]. The IDH1 inhibitor ivosidenib is also approved for newly diagnosed patients who are older or ineligible for IC, and patients with R/R disease [[49](#_ENREF_49),[50](#_ENREF_50)]. A phase 1 study investigated ivosidenib in patients aged ≥18 with *IDH1*-mutated AML; the trial included a cohort of patients who were aged ≥75 or who were ineligible for IC due to comorbidities [[49-51](#_ENREF_49)]. mOS in the primary population was 8.8 months and 21.6% achieved CR [[51](#_ENREF_51)]. Common all-causality AEs were diarrhea (33.3%), leukocytosis (30.2%), and nausea (29.5%) [[51](#_ENREF_51)].

The antibody-drug conjugate gemtuzumab ozogamicin (GO) and the IDH2 inhibitor enasidenib are not yet approved by the FDA and EMA for newly diagnosed patients with AML who are ineligible for IC [[52-55](#_ENREF_52)]; however, they have been investigated in these patients in clinical trials. The phase 3 EORTC-GIMEMA study evaluated GO (6 mg/m2 on day 1, and 3 mg/m2 on day 8) versus best supportive care in elderly patients ineligible for IC [[56](#_ENREF_56)]. Patients were aged >75 or 61$–$75 with a World Health Organization (WHO) performance score >2 or otherwise ineligible for IC. mOS was 4.9 (GO) and 3.6 (best supportive care) months; 8.1% of patients receiving GO achieved CR. Common all-causality non-hematologic AEs with GO and best supportive care, respectively, were liver (51.3% and 45.6%), fatigue (45.9% and 60.5%), and infection (44.1% and 42.1%) [[56](#_ENREF_56)]. In patients aged ≥18 with previously untreated *IDH2*-mutated AML ineligible for standard treatments (criteria not specified; at the discretion of the investigator), mOS was 11.3 months and 18% achieved CR with enasidenib [[57](#_ENREF_57)]. Common all-causality AEs were fatigue (44%), decreased appetite (41%), nausea (38%), and constipation (38%) [[57](#_ENREF_57)].

***Summary***

Although similarities were observed across key clinical studies (comorbidities were an important criterion for determining ineligibility for IC; older patients tended to present with intermediate or adverse cytogenetic risk at baseline), there were large differences in inclusion/exclusion criteria and definitions for ineligibility for chemotherapy (where this was defined). Therefore, baseline characteristics varied greatly across key studies. This heterogeneity in patient populations makes cross-study comparisons inadequate and inadvisable as a guide for treatment selection in older patients with AML.

**Considerations for glasdegib treatment selection**

Dysregulation of the Hedgehog signaling pathway, and its component, SMO, play an important role in AML pathogenesis and the persistence of leukemic stem cell (LSC) populations [[58-61](#_ENREF_58)]. Based on the known mechanism of action of SMOi, glasdegib may eradicate early LSC progenitor populations by reducing LSC dormancy and promoting the differentiation and cell cycle progression of LSCs [[62](#_ENREF_62),[63](#_ENREF_63)].

Glasdegib plus LDAC use is dependent on clinical and patient factors, comorbidities, and concomitant medications (Table 5). Results from BRIGHT MDS&AML 1003 that have helped inform the use of glasdegib plus LDAC are presented in Table 4.

***Baseline risk factors and disease characteristics***

Age is important but should not be the only selection criterion, except perhaps in the upper range [[13](#_ENREF_13),[15](#_ENREF_15),[17](#_ENREF_17)]. However, increased age is generally associated with poorer outcomes. Older patients may have poorer ECOG PS and general health and present with specific comorbidities that can impact treatment tolerability [[2](#_ENREF_2),[8](#_ENREF_8),[13](#_ENREF_13),[15-17](#_ENREF_15)]. Concerns surrounding use of IC in older patients with AML stems from the risk of prolonged myelosuppression and high mortality [[13](#_ENREF_13),[19-29](#_ENREF_19)]. In this context, glasdegib plus LDAC can be considered a first-line treatment for patients aged ≥75 [[34](#_ENREF_34)].

Although glasdegib plus LDAC is approved for patients ineligible for IC, no standard guidelines exist to determine IC eligibility. The BRIGHT MDS&AML 1003 study pre-specified the criteria used to consider a patients to be ineligible for IC, making it more objective than most other studies. Available evaluation tools include the hematopoietic cell transplantation–specific or Charlson comorbidity indexes [[9](#_ENREF_9),[13](#_ENREF_13),[15](#_ENREF_15),[17](#_ENREF_17)], and models incorporating multiple characteristics [[9](#_ENREF_9),[13](#_ENREF_13),[17](#_ENREF_17),[64-67](#_ENREF_64)]. Irrespective of the guidelines used, lower-intensity treatments such as glasdegib plus LDAC or venetoclax plus HMAs can be considered for patients with AML ineligible for IC due to existing comorbidities.

Patients with sAML tend to have a poor prognosis, with reduced CR rates and OS [[68-71](#_ENREF_68)]. BRIGHT MDS&AML 1003 demonstrated glasdegib plus LDAC efficacy in older patients with sAML; CPX-351 is another option, but should be administered only to patients who are eligible for IC and able to withstand prolonged myelosuppression.

Although glasdegib plus LDAC may be effective in patients with therapy-targetable mutations, treatments based on FLT3 or IDH inhibitors should be given priority consideration when mutations of those genes are identified.

***Comorbidities***

In a renal impairment study, participants with moderate or severe impairment had similar pharmacokinetic (PK) parameters following a single glasdegib 100-mg dose [[72](#_ENREF_72)].Coupled with the known safety profile of glasdegib [[36](#_ENREF_36),[37](#_ENREF_37)], this suggests lower starting doses (<100 mg) may not be required in renal impairment. Glasdegib is largely eliminated through hepatic metabolism [[73](#_ENREF_73)]. In a population PK analysis, glasdegib PK was unaffected by mild hepatic impairment [[74](#_ENREF_74)]. In a hepatic impairment study, moderate or severe (Child-Pugh class B or C) impairment did not have a clinically meaningful effect on glasdegib exposure following a single 100-mg dose, although long-term data are warranted [[75](#_ENREF_75)]. Together with previous studies, these data suggest dose modifications are not required in hepatic impairment [[75](#_ENREF_75)].

In patients ineligible for IC, cytopenias occurred more frequently with glasdegib plus LDAC versus LDAC but were not accompanied by increased rate of sepsis or bleeding [[38](#_ENREF_38)]. It is thought that higher absolute rates of cytopenia were due to longer treatment duration with glasdegib plus LDAC compared with LDAC [[36](#_ENREF_36)]. With cytopenia rates adjusted to exposure, transfusion requirements were lower in patients treated with glasdegib plus LDAC. Glasdegib plus azacitidine did not substantially increase hematologic toxicities, cytopenic complications, or AEs related to cytopenias versus azacitidine [[41](#_ENREF_41)]. As a result of the prolonged myelosuppression reported with hypomethylating agents plus venetoclax, glasdegib plus LDAC can be a treatment option when the treating physician considers the patient to be at higher risk of prolonged cytopenias, or when there might be limited access to transfusions or emergency care for neutropenia-related infections. Additionally, glasdegib plus LDAC is an alternative for patients ineligible for venetoclax due to risk of severe, long-lasting myelosuppression or previous toxicities with venetoclax.

Prior to initiating treatment in older patients or those unfit for IC, evaluate medical history and comorbidities regarding AEs commonly associated with SMOi, including alopecia, muscle spasms, musculoskeletal pain, and gastrointestinal AEs [[34](#_ENREF_34),[76-79](#_ENREF_76)]. Patients should be educated on AE signs, symptoms, and appropriate management strategies. Prophylactic or supportive-care therapies should be initiated with glasdegib plus LDAC treatment. As an oral medication, glasdegib does not require in-clinic administration and may be preferred for frail patients, particularly when transfusions or IV administration will affect quality of life (QoL).

***Concomitant medications***

A full review of concomitant medications is essential to identify potential drug-drug interactions with glasdegib and modify treatment plans appropriately before initiating therapy.

Patients undergoing treatment for AML are at increased risk of fungal infections; antifungal agents are routinely used to manage this or as prophylaxis [[80](#_ENREF_80)]. Azoles, the most commonly administered antifungals [[80](#_ENREF_80)], inhibit cytochrome P450 (CYP) 3A4, and glasdegib is largely metabolized by the CYP system. In a healthy participant study, coadministration of glasdegib with ketoconazole elicited 140% and 40% increases in glasdegib plasma exposure and peak concentration, respectively [[73](#_ENREF_73),[81](#_ENREF_81)]. In BRIGHT MDS&AML 1003, comparisons between patients who received CYP3A4 inhibitors versus those who did not were limited due to differences in exposure; however, rates of AEs and grade 3–4 AEs were 93.3% versus 100%, and 90% versus 82.5%, respectively (unpublished data). The glasdegib product label advises use of alternatives to strong CYP3A inhibitors [[34](#_ENREF_34)]. However, if coadministration is required, modify doses and monitor patients for AEs. The benefit of antifungals outweighs the risks; monitor the corrected QT interval (QTc) after 1, 2, and 4 weeks when azoles are coadministered with glasdegib.

Glasdegib exposure and plasma concentrations in healthy participants are ≈70% and 35% lower, respectively, when coadministered with the CYP3A4 inducer rifampin [[82](#_ENREF_82)]. Avoid concomitant use of glasdegib with strong CYP3A4 inducers (e.g. rifampin, bosentan, dexamethasone, carbamazepine, phenytoin) [[34](#_ENREF_34)]; dexamethasone should not be used as an antiemetic in patients receiving glasdegib. If coadministration with moderate CYP3A4 inducers is required, modify doses and monitor patients for AEs [[34](#_ENREF_34)].

Avoid coadministration of glasdegib with QT-prolonging agents (e.g. antiarrythmics, antimalarials, macrolides). If coadministration is necessary, monitor patients for QT prolongation [[34](#_ENREF_34)]; monitor potassium and magnesium closely and correct abnormalities.

Two studies in healthy participants demonstrated that glasdegib can be administered with proton pump inhibitors, irrespective of food intake [[83](#_ENREF_83),[84](#_ENREF_84)], which simplifies dosing recommendations and may facilitate adherence. Allopurinol, furosemide, and paracetamol may also be coadministered with glasdegib [[36](#_ENREF_36)].

***Response monitoring***

Patients should not be removed from glasdegib plus LDAC treatment due to lack of CR alone. Improvement (e.g. in transfusion requirements) in the absence of CR is compatible with, but not confirmatory for, glasdegib’s action on LSCs rather than as a cytotoxic agent [[34](#_ENREF_34)]. The panel recommended, in the absence of AML progression, patients receive ≥6 treatment cycles per product label, even if CR is not observed by cycle 2–3, particularly if other clinical benefits are seen.

**Managing AEs associated with glasdegib plus LDAC**

The most common AEs with glasdegib (Table 5 and Figure 2) are related to the mechanism of action of SMOi [[85-90](#_ENREF_85)], although frequency and severity varies due to different PK properties. Most can be managed with dose modifications and/or temporary interruptions; however, alternative strategies are available (Table 6) [[34](#_ENREF_34),[76-79](#_ENREF_76)]. In general, complete blood counts, electrolytes, and renal and hepatic function should be assessed prior to initiating treatment and at least weekly for the first month. Electrolytes and renal function should be monitored monthly throughout treatment [[34](#_ENREF_34)].

Common non-hematologic AEs observed during glasdegib treatment include alopecia, dysgeusia, fatigue, gastrointestinal AEs, muscle spasms, and rash (Table 5) [[36](#_ENREF_36)]. It is important to inform patients of the possibility of these AEs and that they are common with SMOi treatment. Additionally, a full review of the patient’s medical history, comorbidities, underlying deficiencies, and concomitant medications should be completed before initiating treatment to identify contributory factors for AEs. Pharmacologic/supportive care therapies or nonpharmacologic management strategies should be considered, and existing treatments may need modified, either prophylactically or in the event of an AE [[76-79](#_ENREF_76)]. Patients should be advised to maintain healthy physical activity, and nutritional and sleeping habits. Guidance should be provided on any behavioral changes that can minimize the risk of certain AEs[[76-79](#_ENREF_76)]. If necessary, AEs can be managed by reducing or interrupting the glasdegib and/or LDAC dose [[34](#_ENREF_34)].

For non-hematologic grade 3 AEs, glasdegib and/or LDAC should be interrupted until symptoms become mild or return to baseline [[34](#_ENREF_34)]. Glasdegib can then be resumed at the same dose level or reduced to 50 mg. If toxicity recurs once, the dose should be reduced (if not done previously), and treatment should be discontinued upon second recurrence. If the AE is glasdegib related, LDAC may be continued, or vice versa [[34](#_ENREF_34)]. Treatment should be discontinued in the event of non-hematologic grade 4 AEs [[34](#_ENREF_34)].

Although glasdegib is associated with anemia and thrombocytopenia [[36](#_ENREF_36)], these conditions are often present at baseline and causality is difficult to assess in the setting of active leukemia. Patients should be monitored regularly for myelosuppression and be advised of the potential for hematologic AEs. Ensuring that patients report symptoms (e.g. bruising easily, unexpected bleeding, blood in urine or stools, fever, extreme fatigue) can help identify AEs early in the treatment process. As detailed in the product label, glasdegib plus LDAC should be permanently discontinued with platelets <10×109/L and neutrophil count <0.5×109/L for >42 days in the absence of persistent disease [[34](#_ENREF_34)]. Transfusions, granulocyte colony-stimulating factor, and antibacterial prophylaxis should be used per local guidelines.

The possibility of febrile neutropenia and associated complications increases with age, poor WHO performance score, and comorbidities [[91](#_ENREF_91)]. Prophylactic antimicrobial treatment should be considered in at-risk patients and patients should be advised to report symptoms promptly (e.g. increased body temperature, chills, sweating) [[91](#_ENREF_91)]. For management, granulocyte colony-stimulating agents should be considered, particularly with difficult-to-control infections. In the event of neutropenic fever, patients should report immediately to the clinic or emergency center. Prompt assessment, identification, and treatment with antimicrobial therapy is important (e.g. intravenous broad spectrum antibiotics ≤1 hour of occurrence), as well as ongoing monitoring of response, with therapy plan modifications as appropriate [[91](#_ENREF_91)].

QTc prolongation is uncommon but needs awareness. In addition to monitoring electrolyte levels (particularly magnesium and potassium) and electrocardiograms (ECGs) throughout treatment, evaluating patients for comorbidities and QT-prolonging concomitant medications is important. Further details on managing specific QTc interval events are shown in Table 6 [[34](#_ENREF_34)]. A pooled analysis of glasdegib trials (*N*=412) revealed no events of torsades de pointes (unpublished data).

Other AEs listed on the product label are dyspnea, edema, and hemorrhage (each ≥20% in product label). It is important to discuss the possibility of AEs with patients prior to treatment initiation, evaluate comorbidities and concomitant medications that may lead to increased risk of AEs, and ensure patients are given the necessary information on AE signs and symptoms. Weight loss (<20% in BRIGHT MDS&AML 1003) is multifactorial and may result from other AEs or leukemia itself. As some patients may view weight loss as desirable rather than an AE, emphasize the importance of reporting any changes in body weight [[34](#_ENREF_34),[76-79](#_ENREF_76)].

**Summary**

Glasdegib is the first SMOi approved for treatment of AML and targets the LSC population that can persist following standard chemotherapy. Treatment selection is multifactorial and includes patient age, comorbidities, concomitant medications, and risk factors. In contrast with other therapies, glasdegib 100 mg QD plus LDAC 20 mg BID can be considered for older patients (≥75) and patients with poorer risk profiles and prognostic scores, ineligible for IC, with sAML, or who received prior HMAs for MDS. As an oral medication, glasdegib does not require in-clinic administration. Additionally, glasdegib plus LDAC can be administered to patients with renal or hepatic impairment and severe cardiac disease. Prior to treatment initiation, a full evaluation of medical history, concomitant medications, and comorbidities should be performed. Patients should be educated on common AEs and mitigation strategies and regularly monitored for AEs during treatment. Key management strategies for common treatment-related AEs are dose modifications and interruptions. Effective AE management can lead to improved patient outcomes, QoL, and medication adherence.

**Funding**

The authors were not paid for the development of this manuscript. The authors had final authority, including choice of journal, on all aspects of the manuscript content and development. Pfizer funded the medical advisory board meeting for the discussion of treatment decision-making in AML, and provided a formal review of the publication, including for medical accuracy. The experts were compensated for expenses for their attendance at the medical advisory board meeting, from which the authors decided to proceed with the preparation of the manuscript; however, they were not compensated for manuscript preparation.

The BRIGHT AML 1003 trial reviewed in this article is a clinical study sponsored by Pfizer.

**Acknowledgments**

The authors would like to thank B. Douglas Smith for his contributions to the advisory board discussions. Medical writing support, under the direction of the authors, was provided by Anne Marie McGonigal, PhD, of Engage Scientific Solutions, and funded by Pfizer.

**Author contribution**

All authors participated in discussions regarding treatment decision-making in AML. All authors contributed to developing and correcting the draft manuscript, and provided additional recommendations. All authors read and approved the final manuscript.

**Disclosure of interest**

* Jorge E. Cortes: consultant for Astellas Pharma, Bristol-Myers Squibb, Daiichi Sankyo, Forma Therapeutics, Novartis, Pfizer, Takeda; research funding to institution from Amphivena Therapeutics, Astellas Pharma, Bristol-Myers Squibb, Daiichi Sankyo, Forma Therapeutics, Immunogen, Merus, Novartis, Pfizer, Sun Pharma, Takeda.
* Anna Candoni: honoraria from Novartis, Janssen, Pfizer, Gilead, Celgene, Incyte, Merck.
* Richard E. Clark: research funding from Novartis, Bristol-Myers Squibb, Pfizer; advisory board member for Novartis, Bristol-Myers Squibb, Jazz Pharmaceuticals, AbbVie, Pfizer; honoraria from Novartis, Bristol-Myers Squibb, Pfizer.
* Michael Heuser: honoraria from Novartis, Pfizer, PriME Oncology; consulting or advisory role for Abbvie, Bayer Pharma AG, Daiichi Sankyo, Novartis, Pfizer; research funding to institution from Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Karyopharm, Novartis, Pfizer, Roche.
* Brian Leber: consultancy for Novartis; honoraria from AbbVie, Alexion, Astellas, Celgene, Jazz Pharmaceuticals, Novartis, Pfizer; advisory board member for AbbVie, Alexion, Astellas, Celgene, Jazz Pharmaceuticals, Novartis, Pfizer; speaker’s bureau member for AbbVie, Alexion, Astellas, Celgene, Novartis, Pfizer.
* Pau Montesinos: advisory board member for Celgene, Jazz, Janssen, Novartis; funding from Pfizer, Celgene.
* Paresh Vyas: research funding from Celgene, CD47 Inc; honoraria from Celgene, Pfizer, Astellas, Daiichi Sankyo, Novartis.
* Amer M. Zeidan: received research funding (institutional) from Celgene, AbbVie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics; consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Jazz, Incyte, Agios, Boehringer Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, and Epizyme; travel support for meetings from Pfizer, Novartis, and Trovagene.

**References**

[1] De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.

[2] Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447.

[3] Gu R, Yang X, Wei H. Molecular landscape and targeted therapy of acute myeloid leukemia. Biomark Res. 2018;6:32.

[4] Martignoles JA, Delhommeau F, Hirsch P. Genetic hierarchy of acute myeloid leukemia: from clonal hematopoiesis to molecular residual disease. Int J Mol Sci. 2018;19:pii: E3850.

[5] Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53-61.

[6] Bohl SR, Bullinger L, Rücker FG. New targeted agents in acute myeloid leukemia: new hope on the rise. Int J Mol Sci. 2019;20:1983.

[7] Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593-606.

[8] NCCN Practice Guidelines in Oncology: Acute Myeloid Leukemia [Internet]. National Comprehensive Cancer Network; 2019 [cited 2019 Mar 26]. Available from: <https://www.nccn.org/professionals/physician_gls/pdf/aml_blocks.pdf>

[9] Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27:997-999.

[10] Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:721-749.

[11] Brandwein JM, Zhu N, Kumar R, et al. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. Am J Blood Res. 2017;7:30-40.

[12] Finn L, Dalovisio A, Foran J. Older patients with acute myeloid leukemia: treatment challenges and future directions. Ochsner J. 2017;17:398-404.

[13] Sanford D, Ravandi F. Management of newly diagnosed acute myeloid leukemia in the elderly: current strategies and future directions. Drugs Aging. 2015;32:983-997.

[14] Kantarjian H. Acute myeloid leukemia—major progress over four decades and glimpses into the future. Am J Hematol. 2016;91:131-145.

[15] Pettit K, Odenike O. Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies. Front Oncol. 2015;5:280.

[16] NCCN Practice Guidelines in Oncology: Older Adult Oncology [Internet]. National Comprehensive Cancer Network; 2019 [cited 2019 Jun 25]. Available from: <https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf>

[17] Klepin HD, Estey E, Kadia T. More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate. Am Soc Clin Oncol Educ Book. 2019;39:421-432.

[18] Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376:2000-2008.

[19] Medeiros BC, Satram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol. 2015;94:1127-1138.

[20] Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish acute leukemia registry. Clin Lymphoma Myeloma Leuk. 2011;11:S54-S59.

[21] Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179-4187.

[22] Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916-1924.

[23] Sorror ML, Storer BE, Elsawy M, et al. Intensive versus non-intensive induction therapy for patients (pts) with newly diagnosed acute myeloid leukemia (AML) using two different novel prognostic models. Blood. 2016;128:216.

[24] Bell JA, Galaznik A, Farrelly E, et al. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent. Leuk Res. 2019;78:45-51.

[25] Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27:4747-4753.

[26] Ross K, Gillespie-Twardy AL, Agha M, et al. Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia. Oncol Res. 2015;22:85-92.

[27] Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116:4422-4429.

[28] Kim I, Koh Y, Yoon SS, et al. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. Am J Hematol. 2013;88:10-15.

[29] Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235-1248.

[30] Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;

[31] Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114-1124.

[32] Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670-2677.

[33] Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291-299.

[34] Highlights of prescribing information: Daurismo (glasdegib) [Internet]. US Food and Drug Administration; 2020 [cited 2020 27 March]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210656s002s004lbl.pdf>

[35] Summary of opinion (initial authorisation): Daurismo (glasdegib) [Internet]. European Medicines Agency; 2020 [cited 2020 May 06]. Available from: <https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-daurismo_en.pdf>

[36] Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379-389.

[37] Heuser M, Fiedler W, Sekeres MA, et al. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase 2 randomized trial. Clin Lymphoma Myeloma Leuk. 2019;19:S231.

[38] Papayannidis C, Smith BD, Heuser M, et al. Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. Clinical Lymphoma, Myeloma and Leukemia. 2019;19:S228-S229.

[39] Cortes J, Heidel FH, Fiedler W, et al. Glasdegib improved overall survival in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who achieved complete remission (CR) and those who did not achieve CR. 2018 Stockholm, Sweden.

[40] Kwon Y, Bell TJ, Solem C, et al. Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis. Blood. 2019;134:2610-2610.

[41] Zeidan A, Schuster MW, Krauter J, et al. Clinical benefit of glasdegib in combination with azacitidine or low-dose cytarabine in patients with acute myeloid leukemia. Abstract at 62nd ASH Annual Meeting & Exposition; 2019 Dec 5–8; San Diego (CA, USA).

[42] Sekeres MA, Schuster MW, Joris M, et al. A phase 1b study of glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Abstract at 62nd ASH Annual Meeting & Exposition; 2019 Dec 5–8; San Diego (CA, USA).

[43] Highlights of prescribing information: Venclexta (venetoclax) [Internet]. US Food and Drug Administration; 2018 [cited 2019 Mar 19]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208573s009lbl.pdf>

[44] DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7-17.

[45] Wei AH, Strickland SA, Jr., Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib/II study. J Clin Oncol. 2019;37:1277-1284.

[46] AbbVie. AbbVie provides update from phase 3 study evaluating VENCLEXTA® (venetoclax) in combination with low-dose cytarabine in newly-diagnosed patients with acute myeloid leukemia (AML) [Internet]. AbbVie; 2020 [cited 2020 March 27]. Available from: <https://news.abbvie.com/news/press-releases/abbvie-provides-update-from-phase-3-study-evaluating-venclexta-venetoclax-in-combination-with-low-dose-cytarabine-in-newly-diagnosed-patients-with-acute-myeloid-leukemia-aml.htm>

[47] Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18:17.

[48] Papayannidis C, Sartor C, Marconi G, et al. Acute myeloid leukemia mutations: therapeutic implications. Int J Mol Sci. 2019;20:pii: E2721.

[49] Highlights of prescribing information: Tibsovo (ivosidenib) [Internet]. US Food and Drug Administration; 2018 [cited 2019 Sep 13]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf>

[50] Public summary of opinion on orphan designation: ivosidenib [Internet]. European Medicines Agency; 2017 [cited 2019 Mar 22]. Available from: <https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/16/1802-public-summary-opinion-orphan-designation-ivosidenib-treatment-acute-myeloid-leukaemia_en.pdf>

[51] DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386-2398.

[52] Highlights of prescribing information: Mylotarg (gemtuzumab ozogamicin) [Internet]. US Food and Drug Administration; 2017 [cited 2019 Mar 22]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf>

[53] Summary of product characteristics: Mylotarg (gemtuzumab ozogamicin) [Internet]. European Medicines Agency; 2019 [cited 2019 Mar 22]. Available from: <https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf>

[54] Highlights of prescribing information: Idhifa (enasidenib) [Internet]. US Food and Drug Administration; 2017 [cited 2019 Mar 22]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf>

[55] Highlights of prescribing information: Xospata (gilteritinib) [Internet]. US Food and Drug Administration; 2018 [cited 2019 Mar 22]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf>

[56] Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34:972-979.

[57] Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33:2575-2584.

[58] Campbell V, Copland M. Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning. 2015;8:27-38.

[59] Ok CY, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol. 2012;180:2-11.

[60] Khan AA, Harrison CN, McLornan DP. Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase? Br J Haematol. 2015;170:323-335.

[61] Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129:1627-1635.

[62] Tauchi T, Okabe S, Katagiri S, et al. Targeting the Hedgehog signaling pathway by glasdegib limits the self-renewal of MDS-derived induced potent stem cells (iPSC). J Cancer Sci Ther. 2017;9:479-484.

[63] Fukushima N, Minami Y, Kakiuchi S, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107:1422-1429.

[64] AML-SCORE [Internet]. Study Alliance Leukemia; 2019 [cited 2019 Sep 13]. Available from: <https://www.aml-score.org>

[65] Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93:1267-1291.

[66] Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417-4423.

[67] Walter RB, Othus M, Orlowski KF, et al. Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica. 2018;103:e106-e109.

[68] Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007;20:29-37.

[69] Granfeldt Ostgard LS, Medeiros BC, Sengelov H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641-3649.

[70] Boddu PC, Kantarjian HM, Ravandi F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017;123:3050-3060.

[71] Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017;1:1312-1323.

[72] Shaik MN, LaBadie RR, Hee B, et al. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib. In: *American Society for Clinical Pharmacology and Therapeutics - 121st Annual Meeting (CANCELED).* (Ed.^(Eds) (Clinical Pharmacology and Therapeutics, 2020) PII-126.

[73] Lam JL, Vaz A, Hee B, et al. Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017;47:1064-1076.

[74] Lin S, Shaik N, Martinelli G, et al. Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. J Clin Pharmacol. 2019;

[75] Masters JC, LaBadie RR, Salageanu J, et al. Pharmacokinetics (PK) and safety of glasdegib in participants with moderate and severe hepatic impairment: Phase 1, open-label, single-dose, parallel-group study. In: *American Society for Clinical Pharmacology and Therapeutics - 121st Annual Meeting (CANCELED).* (Ed.^(Eds) (Clinical Pharmacology and Therapeutics, 2020) PIII-049.

[76] Lacouture ME, Dreno B, Ascierto PA, et al. Characterization and management of Hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21:1218-1229.

[77] Yang X, Dinehart BA. Practical tips for managing Hedgehog pathway inhibitor side effects [Internet]. Practical Dermatology; 2017 [cited 2019 Sep 16]. Available from: <http://v2.practicaldermatology.com/pdfs/pd0117_CF_BCC.pdf>

[78] Mohan SV, Chang AL. Management of cutaneous and extracutaneous side effects of Smoothened inhibitor therapy for advanced basal cell carcinoma. Clin Cancer Res. 2015;21:2677-2683.

[79] Jacobsen AA, Kydd AR, Strasswimmer J. Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma. J Am Acad Dermatol. 2017;76:767-768.

[80] Maertens JA, Girmenia C, Bruggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221-3230.

[81] Shaik MN, LaBadie RR, Rudin D, et al. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers. Cancer Chemother Pharmacol. 2014;74:411-418.

[82] Shaik MN, Hee B, Wei H, et al. Evaluation of the effect of rifampin on the pharmacokinetics of the smoothened inhibitor glasdegib in healthy volunteers. Br J Clin Pharmacol. 2018;84:1346-1353.

[83] Giri N, Lam LH, LaBadie RR, et al. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers. Cancer Chemother Pharmacol. 2017;80:1249-1260.

[84] Shaik N, Hee B, Wei H, et al. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study. Cancer Chemother Pharmacol. 2019;83:463-472.

[85] Summary of product characteristics: Odomzo (sonidegib) [Internet]. European Medicines Agency; 2018 [cited 2019 Mar 18]. Available from: <https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf>

[86] Summary of product characteristics: Erivedge (vismodegib) [Internet]. European Medicines Agency; 2019 [cited 2019 Mar 18]. Available from: <https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf>

[87] Highlights of prescribing information: Erivedge [Internet]. US Food and Drug Administration; 2012 [cited 2019 Mar 18]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf>

[88] Highlights of prescribing information: Odomzo [Internet]. US Food and Drug Administration; 2016 [cited 2019 Mar 18]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205266s002lbl.pdf>

[89] Basset-Seguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334-348.

[90] Cortes JE, Gutzmer R, Kieran MW, et al. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev. 2019;76:41-50.

[91] Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27:v111-v118.

[92] Highlights of prescribing information: Vidaza (azacitidine) [Internet]. US Food and Drug Administration; 2008 [cited 2019 Sep 11]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050794s011lbl.pdf>

[93] Summary of product characteristics: Vidaza (azacitidine) [Internet]. European Medicines Agency; 2013 [cited 2019 Sep 12]. Available from: <https://www.ema.europa.eu/en/documents/product-information/vidaza-epar-product-information_en.pdf>

[94] Approval letter: cytarabine inection [Internet]. US Food and Drug Administration; 1999 [cited 2019 Sep 16]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/075383.PDF>

[95] Highlights of prescribing information: Dacogen (decitabine) [Internet]. US Food and Drug Administration; 2018 [cited 2019 Sep 11]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf>

[96] Summary of product characteristics: Dacogen (decitabine) [Internet]. European Medicines Agency; 2019 [cited 2019 Sep 12]. Available from: <https://www.ema.europa.eu/en/documents/product-information/dacogen-epar-product-information_en.pdf>

**Table 1.** Summary of agents approved for treatment of patients with AML ineligible for intensive chemotherapy.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Product | Mechanism of action | FDA approval status in AML | Approved dosage | EMA approval status in AML | Approved dosage |
| Azacitidine [[92](#_ENREF_92),[93](#_ENREF_93)] | Hypomethylating agent | Indicated for MDS, including refractory anemia with excess blasts in transformation (i.e. 20–30% blasts), which is now classified as AML per contemporary classification systems | 75 mg/m2 SC or IV daily for 7 days (28-day cycle). Increase to 100 mg/m2 after 2 cycles if no beneficial effect or toxicity observed | Indicated for intermediate-II and high-risk MDS according to the IPSS, AML with 20–30% blasts and multilineage dysplasia, according to WHO classification, and AML with >30% marrow blasts according to WHO classification | 75 mg/m2 SC or IV daily for 7 days (28-day cycle) |
| Cytarabine [[2](#_ENREF_2),[94](#_ENREF_94)] | Nucleoside metabolic inhibitor | Indicated in combination with other approved anticancer drugs for induction in acute non-lymphocytic leukemia of adults and children | 100–200 mg/m2/day cytarabine by continuous IV for 7 days | Historical use | 100–200 mg/m2/day cytarabine by continuous IV for 7 days |
| Decitabine [[95](#_ENREF_95),[96](#_ENREF_96)] | Hypomethylating agent | Indicated for adult patients with MDS, including previously treated and untreated, de novo and secondary MDS of all French/American/British subtypes and intermediate-I, intermediate-II, and high-risk IPSS groups | *4-week cycle:* 20 mg/m2 IV over 60 min for 5 days*6-week cycle:* 15 mg/m2 continuous IV over 3 h, repeated every 8 h, for 3 days | Patients with newly diagnosed de novo or secondary AML, according to WHO classification, who are not candidates for standard induction chemotherapy | 20 mg/m2 IV over 60 min for 5 days (4-week cycle) |
| Glasdegib [[34](#_ENREF_34),[35](#_ENREF_35)] | SMO inhibitor | In combination with LDAC for adult patients with AML aged ≥75 or who have comorbidities that preclude use of intensive induction chemotherapy | 100 mg/day PO | Initial authorization in combination with LDAC for newly diagnosed de novo or secondary AML in adult patients who are notcandidates for standard induction chemotherapy | To be confirmed |
| Ivosidenib [[49](#_ENREF_49),[50](#_ENREF_50)] | IDH1inhibitor | Indicated for treatment of AML with a susceptible *IDH1* mutation in adult patients with newly diagnosed AML who are aged ≥75 or who have comorbidities that preclude use of intensive induction chemotherapy, or adult patients with R/R AML | 500 mg/day PO | Granted orphan designation for treatment of AML | Not applicable |
| Venetoclax [[43](#_ENREF_43)] | BCL-2 inhibitor | In combination with azacitidine or decitabine or LDAC for newly diagnosed AML in adults who are aged ≥75, or who have comorbidities that preclude use of intensive induction chemotherapy | 100 mg (day 1), 200 mg (day 2), 400 mg (day 3), 400 mg (days 4+; in combination with azacitidine or decitabine) or 600 mg (days 4+; in combination with low-dose cytarabine) | Not yet approved for AML | Not applicable |

Details correct as of 10 July 2020.

AML: acute myeloid leukemia; APL: acute promyelocytic leukemia; EMA: European Medicines Agency; FDA: US Food and Drug Administration; IDH: isocitrate dehydrogenase; IPSS: International Prognostic Scoring System; IV: intravenously; LDAC: low-dose cytarabine; MDS: myelodysplastic syndrome; PO: orally; R/R: relapsed or refractory; SC, subcutaneously; SMO: Smoothened; WHO: World Health Organization.

**Table 2.** Summary of eligibility criteria in key clinical trials in patients with AML who are ineligible for intensive treatment.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study design | Treatments | Age | Diagnosis | ECOG PS and cytogenetic risk | Other |
| **Patients ineligible for IC** |
| BRIGHT MDS&AML 1003:* Open-label, multicenter phase 2 study [[36](#_ENREF_36)]
 | * Patients were randomized 2:1 to: glasdegib 100 mg QD + LDAC 20 mg BID (*N*=88) or LDAC 20 mg BID alone (*N*=44)
 | ≥55 | * Newly diagnosed
* Previously untreated AML or high-risk MDS
 | * See Other
* Known cytogenetic profile
 | Considered not suitable for IC, ≥1 of the following criteria: * Age: ≥75
* Serum creatinine: >1.3 mg/dL
* Severe cardiac disease
* ECOG PS=2
* ECOG PS=0 or 1 + ≥1 other criteria listed above
 |
| * Open-label, multicenter, multinational phase 1B/2 study [[45](#_ENREF_45)]
 | * 82 patients received venetoclax 600 mg QD + LDAC 20 mg/m2/day
 | ≥60 | * Previously untreated AML
* Patients with secondary AML or prior treatment with HMAs for MDS were permitted
 | * ECOG PS=0–2 if aged ≥75
* ECOG PS=0–3 if aged 60–74 (if ECOG PS=0–1, another comorbidity was required)
 | * Ineligible for IC due to comorbidity or other factors
* Life expectancy >12 weeks
* White blood cells: ≤25×109/L
* Cardiovascular disability status of NYHA class ≤II
 |
| * Multicenter, phase 1B dose-escalation and expansion study [[44](#_ENREF_44)]
 | * 145 patients received venetoclax at 400, 800, or 1200 mg/day + decitabine 20 mg/m2 or azacitidine 75 mg/m2
 | ≥65 | * Previously untreated AML
 | * ECOG PS=0–2
 | * Adequate renal and hepatic function
* White blood cell count of ≤25×109/L

Ineligible for standard induction chemotherapy due to comorbidities, such as:* Age: >75
* Cardiac disease
* Prior anthracycline use
* Secondary AML
* High probability of treatment-related mortality
 |
| * Prospective randomized study [[31](#_ENREF_31)]
 | * Patients were randomized to LDAC 20 mg BID (*N*=103) or hydroxyurea (*N*=99)
 | ≥60 | * de novo or secondary AML or high-risk MDS
 | Not specified | No specific criteria used to define patients considered not fit for intensive treatment, except:* Patients aged <70 should have a documented comorbidity that precluded chemotherapy
* Patients who entered the non-intensive approach were significantly older, had a poorer performance score, had more secondary disease, and had more heart disease and documented comorbid conditions
 |
| EORTC-GIMEMA AML-19:* Open-label, phase 3 study [[56](#_ENREF_56)]
 | * Patients were randomized 1:1 to a single induction course of GO (6 mg/m2 on day 1 and 3 mg/m2 on day 8; *N*=118) or best supportive care (*N*=119)
 | >75 | * Previously untreated AML (de novo or secondary to myelodysplasia) and who were deemed ineligible for IC
 | * See Other
 | * Age: 61–75 with a WHO performance score >2 or who were unwilling to receive standard chemotherapy
* Serum creatinine and liver function test results (bilirubin and transaminases): ≤1.5×ULN
* White blood cell count: <30×109/L
 |
| Phase 1 multicenter, open-label, dose-escalation and dose-expansion study [[51](#_ENREF_51)] | * 258 patients received ivosidenib 500 mg/day
 | ≥18 | * R/R *IDH1*-mutated AML
 | * ECOG PS=0–2
 | Included a cohort of patients who were ≥75 or who had comorbidities that precluded the use of IC based on ≥1 of the following criteria: * ECOG PS ≥2
* severe cardiac or pulmonary disease hepatic impairment with bilirubin >1.5×ULN
* creatinine clearance <45 mL/min
 |
| Multicenter, open-label, single-arm study [[57](#_ENREF_57)] | * 39 patients received enasidenib 50–650 mg/day
 | ≥18 | * Previously untreated *IDH2*-mutated AML
 | * ECOG PS=0–2
 | * Not candidates for standard AML treatments
 |
| **Older patients** |
| * Multicenter, randomized, open-label, phase 3 study [[32](#_ENREF_32)]
 | * Patients were randomized 1:1 to: decitabine 20 mg/m2/day (*N*=242) or treatment choice (*N*=243; supportive care or cytarabine 20 mg/m2/day)
 | ≥65 | * Previously untreated de novo or secondary AML
 | * ECOG PS=0–2
* Poor- or intermediate-risk cytogenetics
 | * >30% bone marrow blasts
* White blood cell count: ≤15/mm
* Not considered eligible for HSCT
 |
| * Multicenter, randomized, open-label, phase 3 study [[33](#_ENREF_33)]
 | * Patients were randomized 1:1 to azacitidine 75 mg/m2/day (*N*=241) or conventional care regimens (*N*=247; standard induction chemotherapy, LDAC, or supportive care only)
 | ≥65  | * de novo or secondary AML
 | * ECOG PS=0–2
* Poor- or intermediate-risk cytogenetics
 | * White blood cell count: ≤40,000/mm
* Bilirubin: ≤1.5×ULN
* AST/ALT: ≤2.5×ULN
* Creatinine clearance: ≥40 mL/min
* Life expectancy ≥12 weeks
* Exclusion criteria included: unstable angina or NYHA class III/IV congestive heart failure, inaspirable bone marrow, comorbidities or organ dysfunction
 |

7+3: cytarabine 100 mg/m2 IV for 7 days by continuous infusion, and daunorubicin 60 mg/m2 for 3 days; ALT: alanine transaminase; AML: acute myeloid leukemia; AST: aspartate transaminase; BID: twice daily; CMML: chronic myelomonocytic leukemia; ECOG PS: Eastern Cooperative Oncology Group performance status; GFR: glomerular filtration rate; GO: gemtuzumab ozogamicin; HMA: hypomethylating agent; HSCT: hematopoietic stem cell transplant; IC: intensive chemotherapy; IDH: isocitrate dehydrogenase; IV: intravenous; LDAC: low-dose cytarabine; LVEF: left ventricular ejection fraction; MDS: myelodysplastic syndromes; NYHA: New York Heart Association; QD: once daily; QTcF: QT interval corrected for heart rate using Fridericia’s formula; R/R: relapsed or refractory; ULN: upper limit of normal; WHO: World Health Organization.

**Table 3.** Summary of baseline characteristics in key clinical trials in patients with AML who are ineligible for intensive treatment.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Median (range) age, years | ECOG PS | Cytogenetic risk | AML diagnosis | Prior treatment details | Mutations |
| **Patients ineligible for IC** |
| Glasdegib 100 mg QD + LDAC 20 mg BID or LDAC 20 mg BID alone [[36](#_ENREF_36)] | * Glasdegib + LDAC: 77 (63–92)
* LDAC alone: 75 (58–83)
 | For glasdegib + LDAC and LDAC alone, respectively:* 0: 12.5% and 6.8%
* 1: 33.0% and 40.9%
* 2: 53.4% and 52.3%
* Not reported: 1.1% and 0%
 | For glasdegib + LDAC and LDAC alone, respectively:* Good/intermediate risk: 59.1% and 56.8%
* Poor risk: 40.9% and 43.2%
 | For glasdegib + LDAC and LDAC alone, respectively: * AML: 88.6% and 86.4%
* MDS: 11.4% and 13.6%
 | Prior therapy withMDS drug for glasdegib + LDAC and LDAC alone, respectively:* Azacitidine: 14.8% and 18.2%
* Decitabine: 2.3% and 2.3%
 | Genes mutated in ≥10% of patients for glasdegib + LDAC and LDAC alone, respectively:* *CEBPA*: 13.8% and 12.0%
* *DNMT3A*: 25.9% and 24.0%
* *IDH1*: 13.8% and 8.0%
* *IDH2*: 19.0% and 16.0%
* *RUNX1*: 43.1% and 24.0%
* *TET2*: 24.1% and 36.0%
 |
| Venetoclax 600 mg QD + LDAC 20 mg/m2/day [[45](#_ENREF_45)] | 74 (63–90) | * 0: 15%
* 1: 56%
* 2: 28%
* 3: 1%
 | * Intermediate risk: 60%
* Poor risk: 32%
* No mitosis: 8%
 | * de novo: 51%
* Secondary: 49%
 | * Prior HMA treatment: 29%
 | * *TP53*: 14%
* *FLT3*: 23%
* *IDH1/2*: 25%
* *NPM1*: 13%
 |
| Venetoclax at 400, 800, or 1200 mg/day + decitabine 20 mg/m2 or azacitidine 75 mg/m2 [[44](#_ENREF_44)] | 74 (65–86)  | * 0: 22%
* 1: 62%
* 2: 16%
 | * Intermediate risk: 51%
* Poor risk: 49%
 | * de novo: 75%
* Secondary: 25%
 | * Prior hydroxyurea: 12%
 | * *FLT3*: 12%
* *IDH1/IDH2*: 24%
* *NPM1*: 16%
* *TP53*: 25%
 |
| LDAC 20 mg BID or hydroxyurea [[31](#_ENREF_31)] | Age ≥75:* LDAC: 49%
* Hydroxyurea: 48%
 | Performance score for LDAC and hydroxyurea, respectively:* 0: 28% and 26%
* 1: 43% and 44%
* 2: 19% and 16%
* 3: 12% each
* 4: 1% each
 | For LDAC and hydroxyurea, respectively:* Favorable risk: 2% and 1%
* Intermediate risk: 54% and 52%
* Adverse risk: 17% and 24%
* Unknown: 30% and 22%
 | For LDAC and hydroxyurea, respectively:* de novo: 61% and 60%
* Secondary: 28% and 25%
* MDS: 14% and 14%
 | N/A | N/A |
| GO (6 mg/m2 or best supportive care [[56](#_ENREF_56)] | * GO: 77 (62–88)
* Best supportive care: 77 (66–88)
 | WHO performance score for GO and best supportive care, respectively:* 0–1: 64.4% and 64.7%
* 2: 28.8% and 27.7%
* >2: 6.8% and 7.6%
 | For GO and best supportive care, respectively:* Favorable/intermediate risk: 50.0% and 37.8%
* Adverse risk: 28.0% and 26.9%
* Unknown risk: 22.0% and 35.3%
 | For GO and best supportive care, respectively:* de novo: 66.9% and 71.4%
* Secondary: 33.1% and 28.6%
 | N/A | For GO and best supportive care, respectively:* *CD33* <20: 8.5% and 11.8%
* *CD33* 20–80: 49.1% and 48.7%
* *CD33* >80: 40.7% and 39.5%
* Unknown: 1.7% and 0%
 |
| Ivosidenib 500 mg/day [[51](#_ENREF_51)] | * Primary population: 67 (18–87)
* R/R AML population: 67 (18–87)
 | N/A | For the primary and R/R AML populations, respectively:* Favorable risk: 0% each
* Intermediate risk: 53% and 59%
* Poor risk: 30% and 28%
* Unknown/missing: 17% and 13%
 | For the primary and R/R AML populations, respectively:* Primary AML: 66% and 67%

Secondary AML: 34% and 33% | Prior therapy and response to prior therapy for the primary and R/R AML populations, respectively:* IC: 74% and 71%
* Non-IC: 66% and 64%
* Investigational therapy: 30% and 31%
* Relapse after transplantation: 29% and 24%
* Second or later relapse: 16% and 15%
* Disease that was refractory to initial induction
* Reinduction therapy: 69% and 59%

Relapse within 1 year after initial therapy: 10% and 9% | For the primary and R/R AML populations, respectively:* *FLT3*: 8% and 6%
* *NPM1*: 20% and 26%
* *CEBPA*: 3% and 2%
 |
| Enasidenib 50–650 mg/day [[57](#_ENREF_57)] | 77 (58–87)*
 | * 0: 31%
* 1: 46%
* 2: 23%
 | * Intermediate risk: 49%
* Poor risk: 26%
* Missing: 23%
 | * Myelodysplasia-related changes: 36%
* Recurrent genetic abnormalities: 5%
* Therapy-related myeloid neoplasms: 5%
* Not otherwise specified: 51%
* Missing: 3%
 | N/A | *IDH2* mutant allele:* R140: 67%
* R172: 31%
* Other/Missing: 3%

Genes mutated in ≥10% of patients: * *SRSF2*: 53%
* *ASXL1*: 50%
* *STAG2*: 35%
* *RUNX1*: 29%
* *DNMT3A*: 24%
* *TET2*: 15%
* *NRAS*: 12%
 |
| **Older patients** |
| Decitabine 20 mg/m2/day or treatment choice (supportive care or cytarabine 20 mg/m2/day) [[32](#_ENREF_32)] | * Decitabine: 73 (64–89)
* Treatment choice: 73 (64–91)
 | For decitabine and treatment choice, respectively:* 0 or 1: 76.0% and 75.3%
* 2: 24.0% and 24.7%
 | For decitabine and treatment choice, respectively:* Intermediate risk: 63.1% and 63.6%
* Poor risk: 36.1% and 36.0%
 | For decitabine and treatment choice, respectively:* de novo: 64.0% and 64.6%
* Secondary: 36.0% and 34.6%
 | N/A | N/A |
| Azacitidine 75 mg/m2/day or conventional care regimens (standard induction chemotherapy, LDAC, or supportive care only) [[33](#_ENREF_33)]  | * Azacitidine: 75 (64–91)
* Conventional care regimens: 75 (65–89)

  | For azacitidine and conventional care regimens, respectively:* 0 or 1: 77.2% and 76.8%
* 2: 22.8% and 23.2%
 | For azacitidine and conventional care regimens, respectively:* Intermediate risk: 64.3% and 64.5%
* Poor risk: 35.3% and 34.4%
 | For azacitidine and conventional care regimens, respectively:* AML, not otherwise specified: 63.5% and 57.9%
* AML with myelodysplasia-related changes: 31.1% and 33.6%
* AML with therapy-related myeloid neoplasms: 3.3% and 4.9%
* AML with recurrent genetic abnormalities: 2.1% and 3.6%
 | N/A | N/A |

7+3: cytarabine 100 mg/m2 IV for 7 days by continuous infusion, and daunorubicin 60 mg/m2 for 3 days; AML: acute myeloid leukemia; BID: twice daily; CMML: chronic myelomonocytic leukemia; ECOG PS: Eastern Cooperative Oncology Group performance status; GO: gemtuzumab ozogamicin; HMA: hypomethylating agent; HSCT: hematopoietic stem cell transplant; IC: intensive chemotherapy; LDAC: low-dose cytarabine; MDS: myelodysplastic syndromes; N/A: not available; QD: once daily; R/R: relapsed or refractory; SD: standard deviation; WHO: World Health Organization.

**Table 4.** Summary of results from patients ineligible for IC in BRIGHT MDS&AML 1003 (including unpublished data) [[36-39](#_ENREF_36)].

|  |  |  |
| --- | --- | --- |
| Parameter | Glasdegib plus LDAC | LDAC alone |
| **BRIGHT MDS&AML 1003 population – data from [**[**36**](#_ENREF_36)**], except where indicated** | **(*N*=88)** | **(*N*=44)** |
| Patient characteristics, % |  |  |
| Age >75 | 60.2 | 54.5 |
| Comorbidities (unpublished data)Severe cardiac diseaseSerum creatinine >1.3 mg/dL | 65.921.6 | 47.711.4 |
| Concomitant medications (unpublished data) |  |  |
| Most common, *n*AllopurinolParacetamolFurosemide | 544543 | 271719 |
| CYP3A4 inhibitors, *n*Ciprofloxacin/Ciprofloxacin hydrochlorideFluconazoleaVoriconazolePosaconazoleDiltiazem/Diltiazem hydrochlorideItraconazoleClarithromycinKetoconazoleAmiodarone/Amiodarone hydrochlorideVerapamil/Verapamil hydrochlorideErythromycin | 312415134321111 | 914330330210 |
| CYP3A4 inducers, *n*Dexamethasone/Dexamethasone sodium phosphateCarbamazepinePhenytoin | 711 | 000 |
| Drugs with QT-prolongation potentialb, *n*Ondansetron/Ondansetron hydrochlorideLevofloxacin | 4241 | 1215 |
| Median (range) treatment cycles | 3 (1–35) | 2 (1–9) |
| OS, months, median (80% CI) | 8.8 (6.9–9.9) | 4.9 (3.5–6.0) |
| Complete remission, % | 17.0 | 2.3 |
| Common all-causality AEs associated with SMO inhibitors, % |  |  |
| Alopecia | <20 | <20 |
| Dysgeusia | 25.0 | 2.4 |
| Fatigue | 31.0 | 19.5 |
| Gastrointestinal disorders |  |  |
| Nausea | 35.7 | 12.2 |
| Decreased appetite | 33.3 | 12.2 |
| Diarrhea | 27.4 | 22.0 |
| Constipation | 25.0 | 14.6 |
| Vomiting | 21.4 | 9.8 |
| Hematological toxicities |  |  |
| Anemia | 45.2 | 41.5 |
| Febrile neutropenia | 35.7 | 24.4 |
| Thrombocytopenia | 31.0 | 26.8 |
| Musculoskeletal disorders |  |  |
| Muscle spasms | 22.6 | 4.9 |
| Musculoskeletal painc | ≥20 | ≥20 |
| Rashc | ≥20 | ≥20 |
| QTcF >500 msec | 6.0 | 11.8 |
| **BRIGHT AML 1003 population – data from [**[**37-39**](#_ENREF_37)**] and unpublished data** | **(*N*=78)** | **(*N*=38)** |
| Survival probability at 1 year, % | 39.4 | 8.4 |
| Survival probability at 2 years, % | 19.0 | 2.8 |
| Complete remission, % | 19.2 | 2.6 |
| Median (range) time to complete remission, days | 59 (33–919) | 170d |
| Achieved transfusion independence, % | 29.3 | 5.6 |
| Median duration, days | 212 | 144 |
| Median time to ANC ≥1000/µL, days | 27 | 13 |
| Median (range) time to first recovery, days | 27 (7–114) | 13 (8–70) |
| Median time to ANC ≥500/µL, days | 16 | 11 |
| Median (range) time to first recovery, days | 16 (3–143) | 11 (8–119) |
| Median time to platelets ≥100,000/µL, days | 30 | 26 |
| Median (range) time to first recovery, days | 30 (6–171) | 26 (2–56) |
| Median time to platelets ≥50,000/µL, days | 26 | 24 |
| Median (range) time to first recovery, days | 26 (4–141) | 24 (2–119) |

aOne grade 3 AE of prolonged QT interval was considered related to fluconazole.

bFive patients (two receiving a concomitant QT-prolonging medication) had QTcF >480 msec and/or increase >60 msec from baseline, but no event was accompanied by serious arrhythmias.

cFrom glasdegib product label [[34](#_ENREF_34)].

dOnly one patient achieved complete remission; therefore, no range available.
AE: adverse event; ANC: absolute neutrophil count; CI: confidence interval; CYP: cytochrome P450; IC: intensive chemotherapy; LDAC: low-dose cytarabine; OS: overall survival; QTcF: QT interval corrected for heart rate using Fridericia’s formula; SMO: Smoothened.

**Table 5.** Summary of considerations for glasdegib use.

|  |  |
| --- | --- |
| Consideration | Use of glasdegib |
| **Baseline risk factors** |
| Age | * Can be used in patients ≥75
 |
| Cytogenetic risk | * Can be used in patients of all ELN risk groups
 |
| Ineligible for IC | * Can be used in patients who have comorbidities that preclude use of intensive induction chemotherapy
 |
| Secondary AML | * Can be used in patients with secondary AML
 |
| Mutations | * Can be used in patients with AML who do not present with therapy-targeted mutations
 |
| **Comorbidities** |
| General comorbidities | * Can be used in patients who have comorbidities that preclude use of intensive induction chemotherapy
 |
| Cardiac disease | * Can be used in patients with severe cardiac disease
 |
| Renal impairment | * No glasdegib dose adjustment required for mild, moderate, or severe renal impairment
 |
| Hepatic impairment | * No glasdegib dose adjustment required for mild, moderate, or severe hepatic impairment
 |
| Cytopenias | * Can be considered for patients with the possibility of prolonged cytopenias, who may be frail, who experienced toxicities with venetoclax, or who are ineligible for venetoclax treatment
 |
| Gastrointestinal comorbidities | * Evaluate for the potential to increase the risk of gastrointestinal AEs, and ensure that any prophylactic or supportive care therapies are initiated
 |
| Musculoskeletal comorbidities | * Evaluate for the potential to increase the risk of musculoskeletal AEs, and ensure that any prophylactic or supportive care therapies are initiated
 |
| **Concomitant medications** |
| Strong CYP3A inhibitors, e.g. azole antifungals, macrolide antibiotics, protease inhibitors | * If coadministration is necessary, monitor patients for increased risk of AEs
 |
| Strong CYP3A inducers, e.g. bosentan, carbamazepine, dexamethasone, phenytoin, rifampin | * Avoid coadministration
 |
| QTc-prolonging agents, e.g. antiarrythmics, antimalarials, macrolide antibiotics | * Consider alternative therapies, if possible
* If coadministration is necessary, monitor patients for increased risk of QTc prolongation
 |
| Proton pump inhibitors, e.g. omeprazole, lansoprazole, pantoprazole, rabeprazole | * No restrictions on the use of proton pump inhibitors with glasdegib
 |

AE: adverse event; AML: acute myeloid leukemia; CYP: cytochrome P450; ELN: European LeukemiaNet; IC: intensive chemotherapy; QTc: QT interval corrected for heart rate.

**Table 6.** Summary of the management of the most common AEs associated with glasdegib [[34](#_ENREF_34),[76-79](#_ENREF_76)].

|  |  |  |
| --- | --- | --- |
| Adverse event | AE severity | Examples of suggested AE management strategies |
| Alopecia | Grade 0 and general prophylaxis | * Advise patients on the possibility of alopecia, and reassure them that hair typically begins to regrow upon cessation of treatment
* Educate patients with respect to sun protection and the avoidance of certain chemicals/irritants in order to support hair and scalp health
* Assess patients for comorbidities or underlying nutrient deficiencies that may contribute to alopecia
* May consider prophylactic treatment with minoxidil or oral dihydrotestosterone inhibitors
 |
| Grade 1–2 | * May consider treatment with minoxidil or oral dihydrotestosterone inhibitors
* For eyelashes, may consider treatment with bimatoprost
* Suggest the use of a wig/hairpiece or to shave remaining hair
 |
| Dysgeusia  | Grade 0 and general prophylaxis | * Nutritional and dietary assessment prior to initiating treatment
* Educate patients on dietary strategies such as smaller and more frequent meals, use of stronger seasoning and flavor enhancers, and to increase chewing time
* Address any potential issues regarding oral hygiene, postnasal drip, or oral infections
 |
| Grade 1–2 | * Periodic monitoring of zinc levels and supplementation of zinc
* Provide nutritional support
* If fluid intake is poor, assess renal function
 |
| Grade ≥3 | * Employ management strategies listed for grade 1–2 AEs
* Consider glasdegib interruptions or dose modifications as advised in the product label for non-hematologic AEs
 |
| Fatigue | Grade 0 and general prophylaxis | * Assess patients for other symptoms, sleep disturbances, nutritional deficiencies, comorbidities, or concomitant medications that may contribute to fatigue
* Advise patients to maintain regular physical activity
 |
| Grade 1–2 | * Provide access to well-being and mindfulness programs
* Consider rehabilitation and psychology consultations
* Cognitive behavioral therapies or treatment with psychostimulants
* Assess for anemia, and treat if positive
 |
| Grade ≥3 | * Employ management strategies listed for grade 1–2 AEs
* Consider glasdegib interruptions or dose modifications as advised in the product label for non-hematologic AEs
 |
| Gastrointestinal toxicities, e.g. nausea, vomiting, decreased appetite, diarrhea, and constipation | Grade 0 and general prophylaxis | * Patient education on potential symptoms
* Take medication at nighttime or with food
* Eat small meals
* Remain hydrated and minimize caffeine intake
* Include ginger in the diet
* Avoid fatty, fried, or sweet foods
* Avoid pungent odors
 |
| Grade 1–2 | * Treatment with antiemetics, e.g. antidopaminergic (metoclopramide or domperidone), serotonin receptor antagonist (ondansetron), antihistamine (dimenhydrinate), phenothiazine, or steroid medications
* Treatment with antidiarrheal medications, e.g. loperamide and trimebutine
* Treatment with stool softeners for constipation
* Oral fluid replenishment in cases of vomiting and/or diarrhea
 |
| Grade ≥3 | * Employ management strategies listed for grade 1–2 AEs
* Consider glasdegib interruptions or dose modifications as advised in the product label for non-hematologic AEs
 |
| Hematologic toxicities | Grade 0 and general prophylaxis | * Assess complete blood counts prior to treatment initiation and at least weekly for the first month of treatment
* Assess patients for comorbidities or concomitant medications that may contribute to hematologic toxicities
* Patient education on symptom monitoring, e.g. bruising easily, unexpected bleeding, blood in urine or stools
 |
| Platelets <10×109/L for >42 days in the absence of disease | * Permanently discontinue glasdegib treatment
 |
| Neutrophil count <0.5×109/L for >42 days in the absence of disease | * Permanently discontinue glasdegib treatment
 |
| Muscle spasms and musculoskeletal pain | Grade 0 and general prophylaxis | * Obtain serum creatine kinase levels prior to initiating treatment and, where necessary, during treatment, e.g. if muscle symptoms are reported
* Advise the patient to maintain adequate hydration and provide education on passive stretching/gentle physical activity
 |
| Grade 1–2 | * Example non-pharmacologic management includes: massage; heat therapy, e.g. thermal compresses; tonic water or sports drinks as part of fluid intake; transcutaneous electrical nerve stimulation
* Example pharmacologic management includes: electrolyte replacement; calcium channel blockers, e.g. amlodipine; muscle relaxants, e.g. cyclobenzaprine
* In the case of abdominal symptoms: calcium channel blockers or antimuscarinic agents
 |
| Grade ≥3 | * Employ management strategies listed for grade 1–2 AEs
* Consider glasdegib interruptions or dose modifications as advised in the product label for non-hematologic AEs
 |
| QTc prolongation | Grade 0 and general prophylaxis | * Assess electrolyte levels and supplement as clinically indicated
* Assess patients for comorbidities or concomitant medications that may contribute to QTc prolongation
* Monitor ECGs prior to initiation of treatment, for 1 week after treatment initiation, then once monthly for the next 2 months
 |
| QTc interval 480–500 msec | * Review and adjust concomitant medications
* Assess and correct electrolyte abnormalities
* Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation to ≤480 msec
 |
| QTc interval >500 msec | * Review and adjust concomitant medications
* Assess and correct electrolyte abnormalities
* Interrupt glasdegib treatment, and resume glasdegib treatment at a reduced dose of 50 mg QD when QTc interval returns to within 30 msec of baseline or ≤480 msec
* Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation
* Consider re-escalating to glasdegib 100 mg/day if an alternative etiology for the QTc prolongation is identified
 |
| QTc interval prolongation with life-threatening arrhythmia | * Permanently discontinue glasdegib treatment
 |
| Rash | Grade 0 and general prophylaxis | * Patient education on behavioral changes, e.g. avoiding prolonged exposure to hot water and baths, using sunscreen regularly, and avoiding tight clothes
 |
| Grade 1–2 | * Consider supportive care therapies, such as hypoallergenic moisturizing creams and topical therapy in the form of steroids, antiseptics, antibiotics, and/or antihistamines
* Consider support from a dermatologist
 |
| Grade ≥3 | * Employ management strategies listed for grade 1–2 AEs
* Consider glasdegib interruptions or dose modifications as advised in the product label for non-hematologic AEs
 |
| Weight loss | Grade 0 and general prophylaxis | * Nutritional and dietary assessment prior to starting treatment
* Assess patients for risk factors, comorbidities or underlying nutrient deficiencies that may contribute to weight loss
 |
| Grade 1–2 | * Provide nutritional or dietary support
* Treatment with supplements, corticosteroids (excluding dexamethasone), or appetite stimulants, e.g. megestrol acetate or dronabinol
 |
| Grade ≥3 | * Employ management strategies listed for grade 1–2 AEs
* Consider glasdegib interruptions or dose modifications as advised in the product label for non-hematologic AEs
 |

AE: adverse event; ECG: electrocardiogram; QD: once daily; QTc: QT interval corrected for heart rate.

**Figure 1.** Agents approved for treatment of newly diagnosed patients with AML ineligible for intensive chemotherapy.

AML: acute myeloid leukemia; IC, intensive chemotherapy; IDH: isocitrate dehydrogenase; LDAC: low-dose cytarabine.

**Figure 2.** The most common AEs associated with glasdegib.

AE: adverse event.